Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer - Bardia, A; Kaklamani, V; Wilks, S (J Clin Oncol, 2021)